PRESS RELEASES

Date Title and Summary View
Toggle Summary Galectin Therapeutics to Present at BIO CEO & Investor Conference
NORCROSS, Ga. , Feb. 06, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, will present at BIO CEO & Investor Conference on Tuesday,
View HTML
Toggle Summary Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
The broad protection of these patents opens doors to partnerships in the world’s second- and third-largest pharmaceutical markets NORCROSS, Ga. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics , Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to
View HTML
Toggle Summary Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Into 2019
NORCROSS, Ga. , Dec. 19, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it entered into a $10 million unsecured line of credit facility with stockholder and new director Richard E. Uihlein .
View HTML
Toggle Summary Galectin Therapeutics Provides Corporate Update at Annual Meeting
Dr. Peter Traber , CEO and CMO, reviews results of NASH-CX trial that demonstrated statistically significant and clinically meaningful effects in patients who had NASH cirrhosis but did not have esophageal varices Approximately 50% of all patients with NASH cirrhosis do not have esophageal varices
View HTML
Toggle Summary Galectin Therapeutics to Webcast Corporate Update at Annual Meeting of Shareholders
NORCROSS, Ga. , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will present a corporate update via live webcast immediately following the business portion of its 2017
View HTML
Toggle Summary Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
Statistically significant and clinically meaningful effects observed in NASH cirrhosis patients without esophageal varices treated with GR-MD-02 Conference Call at 8:30 A.M. ET to Present Top Line Trial Results NORCROSS, Ga. , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
View HTML
Toggle Summary Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017
Company to Host Investor Conference Call at 8:30 A.M. ET NORCROSS, Ga. , Dec. 04, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, will issue a press release announcing the results of its Phase 2b NASH-CX trial
View HTML
Toggle Summary Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017
NORCROSS, Ga. , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that Peter G. Traber , M.D., the Company's chief executive officer and chief medical officer, has been named the Chair of the
View HTML
Toggle Summary Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial
The objective response rate in advanced melanoma was 62.5% (five of eight subjects) NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute today announced the
View HTML
Toggle Summary Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update
All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial Top Line Results of NASH-CX Phase 2b Clinical Trial Expected to be announced in early December 2017 NORCROSS, Ga. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics
View HTML